Source: Eur Respir J, 54 (5) 1901508; 10.1183/13993003.01508-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Hannah Yejin Kim, Vitali Sintchenko, Jan-Willem Alffenaar. Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?. Eur Respir J, 54 (5) 1901508; 10.1183/13993003.01508-2019

Member's Comments

No comment yet.

Related content which might interest you: Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients Source: Eur Respir J, 53 (4) 1802107; 10.1183/13993003.02107-2018 Year: 2019 Pharmacokinetics of drugs for non tuberculous mycobacterial lung infections Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis Source: Eur Respir J 2016; 47: 1229-1234 Year: 2016 The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease Source: Eur Respir J 2015; 45: 1177-1179 Year: 2015 Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017 Nontuberculous mycobacteria infections in patients receiving immunosuppressive agents Source: Eur Respir Monogr 2018; 81: 238-253 Year: 2018 Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Source: Eur Respir J 2010; 35: 606-613 Year: 2010 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Population pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 In vitro susceptibility of non-tuberculous mycobacterial strains against moxifloxacin Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012 Infection or colonisation: indicators to initiate antimycobacterial treatment in nontuberculous mycobacterial infections Source: Annual Congress 2010 - Advances in the diagnosis of tuberculosis and nontuberculous mycobacterial infections: a joint ERS and ATS symposium Year: 2010 Bedaquiline in the treatment of multi-drug resistant non-tuberculous mycobacteria soft tissue infections: a case series Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021 Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Source: Eur Respir J 2011; 38: 888-894 Year: 2011 A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response Source: Eur Respir J 2004; 23: 741-746 Year: 2004 Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Population pharmacokinetics and pharmacodynamics analysis of vancomycin in patients with severe lower respiratory tract gram-positive infections Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004 Pathogenicity of NTM: new developments Source: Annual Congress 2007 - Nontuberculous mycobacteria (NTM): a slow-growing challenge Year: 2007